I hope you’re right! As a matter of fact, it makes more sense to meet with the board after a new CRO has been picked rather than before.
Perhaps a new CRO has been picked. After all, both KW and the board were already aware of the TD2 dilemma....no need to meet just to beat a dead horse.
Geeze, can you imagine the stress KW has had to endure doing his own dd to re-establish trust in a new CRO all the while safeguarding CiaB’s proprietary information.
If indeed that is the case, then I would think Von Hoff and Practical Clinical guided KW through the selection process to some degree...it would surely save time.
lol I would like to think that at the point of their discussion with the new CRO, where KW asked for a reference, it went like this:
KW: Well, do you have a reference?
new CRO: ahhhh...Dr. Daniel Von Hoff
I mean why not?, he’s been involved in so many trials.
News 
Market Data 
Discover 
